Similar to papillary RCC,16 TRCC harbors high expression of c-MET by immunohistochemistry (IHC).17 Furthermore, TFE3 fusion proteins have been shown to bind to the MET promoter, inducing MET autophosphorylation and activation of downstream signaling in the presence of hepatocyte growth factor (HGF).18 In malignant TRCC cell lines, MET knockdown induces a decrease in proliferation and viability.18 Therefore, targeting MET might represent an interesting option in the clinical setting. The gene discussed is MET; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.